.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The large phase 3 Study 31/A5349 trial tested whether selected rifapentine-based regimens could shorten treatment for drug-susceptible pulmonary tuberculosis from six months to four months. One four-month regimen replaced rifampin with rifapentine and replaced ethambutol with moxifloxacin; a second used rifapentine without moxifloxacin. The rifapentine–moxifloxacin regimen met the prespecified noninferiority criterion against standard six-month therapy, while the rifapentine-only regimen did not. The study is important because shortening treatment duration can reduce pill burden and potentially improve the feasibility of completing therapy, but the regimen must still be matched to the appropriate patient and resistance profile. The paper directly supports the NAPCON tuberculosis symposium's emphasis on treatment strategy, implementation and adherence rather than focusing only on drug selection. For clinicians, the main take-home is that regimen shortening is evidence-based in defined drug-susceptible TB populations, but cannot simply be generalized to drug-resistant disease or to patients outside the studied eligibility criteria. It is a useful example of how modern TB programs can combine regimen innovation with microbiologic assessment and careful follow-up.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The large phase 3 Study 31/A5349 trial tested whether selected rifapentine-based regimens could shorten treatment for drug-susceptible pulmonary tuberculosis from six months to four months. One four-month regimen replaced rifampin with rifapentine and replaced ethambutol with moxifloxacin; a second used rifapentine without moxifloxacin. The rifapentine–moxifloxacin regimen met the prespecified noninferiority criterion against standard six-month therapy, while the rifapentine-only regimen did not. The study is important because shortening treatment duration can reduce pill burden and potentially improve the feasibility of completing therapy, but the regimen must still be matched to the appropriate patient and resistance profile. The paper directly supports the NAPCON tuberculosis symposium's emphasis on treatment strategy, implementation and adherence rather than focusing only on drug selection. For clinicians, the main take-home is that regimen shortening is evidence-based in defined drug-susceptible TB populations, but cannot simply be generalized to drug-resistant disease or to patients outside the studied eligibility criteria. It is a useful example of how modern TB programs can combine regimen innovation with microbiologic assessment and careful follow-up.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
